Slide 17 from the AGM presentation below, highlighted the progress validation of FPP peptide vaccine for subcutaneous melanoma model engineered to express glycoprotein from Herpes Simplex Virus. The company also highlighted the dot point - "Peptide vaccine contains a well characterized CD8+ T cell gBpeptide epitope with and without FPP".
If you go back to the news piece I posted a link to yesterday, take note of what was highlighted in the penultimate paragraph.
"We're excited about the broader clinical implications of this discovery," adds Paulos. "Targeting T cells with CD26 will not only benefit ACT therapy but will also help bolster the effectiveness of other cancer immunotherapies, such as checkpoint modulators, vaccines and cytokine therapies." Paulos explained that human CD4 T cells expressing various amounts of CD26 could also be manipulated in treating patients with infectious diseases and autoimmune manifestations.
I'm now wondering could this new breakthrough discovery of CD4 T Cells expressing high CD26 now be an additional focused area of interest for Phylogica as part of their peptide vaccine validation research?
An exciting breakthrough for cancer immunotherapies.
Tony
PYC Price at posting:
3.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)